-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab Cancer Drug DARZALEX Posts $14.4B in Global Sales in 2025

Benzinga·01/21/2026 11:27:46
Listen to the news

Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 14,351 million in 2025. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.